Patent intelligence · US
US 11478428
Combinations of beta-lactam compounds and probenecid and uses thereof
Combinations of beta-lactam compounds and probenecid and uses thereof
Patent details — US 11478428
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 25, 2022
- Expiration
- Oct 20, 2042
- Claims
- 10
- CPC classes
- A61K, A61K31/195, A61K31/397, A61K31/431
Quick answer
US 11478428 (Combinations of beta-lactam compounds and probenecid and uses thereof) is held by Iterum Therapeutics International Limited. Status: granted. Granted Oct 25, 2022. Expires Oct 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/195, A61K31/397, A61K31/431, A61K9/2013, A61K9/2018
More from Iterum Therapeutics International Limited
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11478428?
US 11478428 (Combinations of beta-lactam compounds and probenecid and uses thereof) is held by Iterum Therapeutics International Limited. Status: granted. Granted Oct 25, 2022. Expires Oct 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11478428?
Iterum Therapeutics International Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 11478428 expire?
Our index shows an expiration date of Oct 20, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.